Monte Rosa Therapeutics I... (GLUE)
NASDAQ: GLUE
· Real-Time Price · USD
6.62
0.29 (4.58%)
At close: Sep 24, 2025, 3:59 PM
6.50
-1.81%
After-hours: Sep 24, 2025, 07:58 PM EDT
4.58% (1D)
| Bid | 6.37 |
| Market Cap | 408.85M |
| Revenue (ttm) | 177.99M |
| Net Income (ttm) | 24.17M |
| EPS (ttm) | 0.39 |
| PE Ratio (ttm) | 16.97 |
| Forward PE | -4.84 |
| Analyst | Hold |
| Dividends | n/a |
| Ask | 6.65 |
| Volume | 710,639 |
| Avg. Volume (20D) | 1,025,279 |
| Open | 6.37 |
| Previous Close | 6.33 |
| Day's Range | 6.37 - 6.68 |
| 52-Week Range | 3.50 - 12.40 |
| Beta | 1.42 |
| Ex-Dividend Date | n/a |
About GLUE
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol GLUE
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for GLUE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsMonte Rosa Therapeutics Inc. is scheduled to release its earnings on
Nov 6, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 week ago
+44.07%
Monte Rosa Therapeutics shares are trading higher ...
Unlock content with
Pro Subscription
11 months ago
+93.87%
Monte Rosa Therapeutics shares are trading higher after the company announced a global license agreement with Novartis to advance VAV1 MGDs. The company will receive a $150 million upfront payment and is eligible for additional milestone payments.
